L’actu Unilabs
Utilisez les filtres ci-dessous pour découvrir toute l’actualité d’Unilabs dans votre région ou par rapport à vos centres d’intérêt.
20 juin 2017Geneva, Porto 19th June 2017. Geneva based Unilabs today announced that it has reached an agreement to acquire CGC Genetics, a leading Medical Genetics Laboratory company serving customers in more than 65 countries, for an undisclosed amount from private equity firm Vallis Capital Partners.
20 mai 2017Unilabs SubHolding AB (publ) (the “Issuer”) today announced that it has priced its offering of €250,000,000 aggregate principal amount of 5.75% senior notes due 2025 (the “Notes”). The offering is expected to close on May 5, 2017.
16 mai 2017European medical diagnostics leader Unilabs reports a strong start into to 2017, delivering the 11th consecutive quarter of EBITDA growth. Commenting on the results, Jos Lamers, Chief Executive Officer stated, “What makes this quarter particularly noteworthy is that we have generated strong growth across both our Lab and Imaging segments as well as our various regions. This is also our 11th consecutive quarter delivering a sustainable organic EBITDA growth.”
20 avril 2017Geneva, Switzerland, based European medical diagnostics leader Unilabs has completed the acquisition of Alpha Medical group from private equity firm Mid Europa Partners for an undisclosed amount. This follows the announcement of the agreement on February 9th, 2017.
9 février 2017Geneva based Unilabs today announced that it has reached an agreement to acquire Alpha Medical, a leading medical diagnostics company serving customers in Slovakia and the Czech Republic, from private equity firm Mid Europa Partners for an undisclosed amount.
8 février 2017Unilabs and funds advised by Apax Partners LLP announce that the purchase by Apax IX of Unilabs shares from Nordic Capital Fund VI and Apax France VII is complete and has now closed following clearance by the European Commission under the EU Merger Regulation.
6 février 2017European medical diagnostics leader Unilabs today announced the departure of its CFO, Karl Erik Clausen. He will leave the company on May 8th, 2017. Philipp Manser has been appointed as his successor.
20 avril 2016Interview de Dany Mercan, responsable de la chimie spéciale. Le diabète de type 2 progresse rapidement et touche de plus en plus de personnes. Sédentarité, malbouffe et surpoids sont en partie responsables.